GlassScriptPhysician profile
Melanie Diaz
NPI 1073631610
$7,718.86
in general payments reported to CMS, 2019-2025
58 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,169 · 2022: $810 · 2023: $2,077 · 2024: $2,023 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,504 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,504.07 |
| Education | $235.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $724.12 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $416.00 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $414.29 | 2021-2025 | Vanflyta, Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $383.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $377.40 | 2022-2025 | Enhertu, Calquence, Lynparza |
| Pharmacosmos Therapeutics INC. | $367.55 | 2023-2025 | Monoferric, Cosela |
| Alexion Pharmaceuticals, INC. | $365.14 | 2021-2025 | Ultomiris |
| Incyte Corporation | $282.36 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Seagen INC. | $253.82 | 2021-2023 | Adcetris |
| Gilead Sciences, INC. | $241.55 | 2023-2025 | Trodelvy |
| Pfizer INC. | $220.44 | 2022-2024 | |
| Celgene Corporation | $213.90 | 2021-2025 | Reblozyl |
| Genzyme Corporation | $212.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $190.92 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Regeneron Healthcare Solutions, INC. | $186.72 | 2021-2023 | Libtayo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.